This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schachter, M. Search for Related Content Social Bookmarking                         What's this?

Review: Blood pressure reduction in the metabolic syndrome and type 2 diabetes: current concepts

Department of Clinical Pharmacology, National Heart and Lung Institute, Imperial College School of Medicine, St Mary's Hospital, London, W2 1NY, UK, m.schachter{at}imperial.ac.uk

ypertension very frequently co-exists with type 2 diabetes and with the metabolic syndrome, though any links regarding underlying pathophysiology remain controversial. However, there is no doubt that the combination greatly increases cardiovascular and renal disease risks. At the same time there is extensive evidence that blood pressure (BP) lowering is a highly effective means of reducing these risks. Current guidelines and other advice emphasise that both the threshold for intervention and the target for BP lowering are below those for the general hypertensive population, at about 130/80 mmHg, but even less in the presence of nephropathy. Blockade of the renin-angiotensin system is considered highly desirable, preferably using angiotensin receptor blockers. Combination drug therapy is almost always needed, and the ABCD rule is helpful as a guide in this respect. The combination of beta blockers and thiazides should usually be avoided, especially in the metabolic syndrome, as it may promote the emergence of overt diabetes. But ultimately the key consideration should be the BP achieved rather than the means required to achieve it.

Key Words: hypertension • diabetes • metabolic syndrome • combination therapy • nephropathy.

References

• Kahn R., Ferrannini E., Buse J., Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005;28;2289-304.
• Zimmet PZ, Alberti G. The metabolic syndrome; perhaps an etiologic mystery but far from a myth - where does the International Diabetes Federation stand? http://www.medscape.com/viewarticle/514211
• Alberti KG, Zimmet P., Shaw J.; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Colhoun HM, Dong W., Barakat MT, Mather HM, Poulter NR The scope for cardiovascular disease risk intervention among people with diabetes mellitus in England: a population based analysis from the Health Surveys for England 1991-94. Diabet Med 1999;16:35-40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stamler J., Vaccaro O., Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.[Abstract]
• UK Prospective Diabetes Study Group. Tight blood pressure control and the risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.[Abstract/Free Full Text]
• Curb JD, Pressel SL, Cutler JA et al. Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92.[Abstract/Free Full Text]
• Davis BR, Langford HG, Blaufox MD, Curb JD, Polk BF, Shulman NB The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. Circulation 1987;75:340-6.[Abstract/Free Full Text]
• Tuomilehto J., Rastenyte D., Birkenhager WH et al. Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and hypertension. N Engl J Med 1999;230:67784.
• Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimised Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Estacio RO, Jeffers BW, Gifford N., Schrier RW Effects of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2):B54-B64.[Web of Science][Medline] [Order article via Infotrieve]
• Williams B., Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40.[Free Full Text]
• Bestermann W., Houston MC, Basile J. et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005;329:292-305.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ravid M., Rachmani R. Cardiovascular protection in patients with type 2 diabetes mellitus: Considerations about the tightness of blood pressure control and the choice of treatment. Eur J Int Med 2005;16:154-9.[CrossRef]
• Choi KL, Bakris GL Hypertension treatment guidelines: practical implications. Semin Nephrol 2005;25:198-209.[Web of Science][Medline] [Order article via Infotrieve]
• Saydah SH, Fradkin J., Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42.[Abstract/Free Full Text]
• Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on CV events in high-risk patients. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.[Abstract/Free Full Text]
• Deedwania PC Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Cardiol Clin 2005; 23:139-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bakris GL Protecting renal function in the hypertensive patient: clinical guidelines. Am J Hypertens 2005;18:112S-119S.[Web of Science][Medline] [Order article via Infotrieve]
• Kopyt NP Slowing progression along the renal disease spectrum. J Am Osteopath Assoc 2005;105:207-15.[Abstract/Free Full Text]
• Waley-Connell A., Sowers JR Hypertension management in type 2 diabetes mellitus: recommendations of the Joint National Committee VII. Endocrinol Metab Clin North Am 2005;34:63-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Welsh L., Ferro A. Drug treatment of essential hypertension: the case for initial combination therapy. In J Clin Pract 2004;58:956-63.[CrossRef]
• Brown MJ, Cruickshank IJK, Dominiczak AF et al. Better blood pressure control: how to combine drugs. J Human Hypertens 2003;17:81-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Laragh JH Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Int 1993;44:1163-75.[Web of Science][Medline] [Order article via Infotrieve]
• Nathan S., Pepine CJ, Bakris GL Calcium antagonists. Effects on cardiorenal risk in hypertensive patients. Hypertension 2005;46:637-42.[Abstract/Free Full Text]
• Carlberg B., Samuellsson O., Lindholm LH Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005;42:S17-S25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dahlof B., Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Abuissa H., Jones PG, Marson SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821-6.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 6, 320-324 (2005)
DOI: 10.1177/14746514050050060401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. R. Black, B. Davis, J. Barzilay, C. Nwachuku, C. Baimbridge, H. Marginean, J. T. Wright Jr., J. Basile, N. D. Wong, P. Whelton, et al. Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Diabetes Care, February 1, 2008; 31(2): 353 - 360. [Abstract] [Full Text] [PDF]

				A. J Krentz Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 303 - 304. [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schachter, M. Search for Related Content Social Bookmarking                         What's this?